Biocept Secures Agreements with Preferred Provider Organizations Stratose and Galaxy Health Network for its Proprietary Blood-Based Oncology Diagnostic Assays
Increases coverage to approximately 31 million PPO members
GHN includes a network of more than 400,000 directly contracted physicians, facilities and hospitals.
"The healthcare community recognizes the importance of determining
molecular biomarker status in making treatment decisions for cancer
patients," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to improvement of patient
outcomes and our impact on diagnostic strategies, such statements are
forward-looking, and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The reader is
cautioned not to put undue reliance on these forward-looking statements,
as these statements are subject to numerous risk factors as set forth in
our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150914005196/en/
Investor Contact:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media